News Updates
More Articles
- Japan’s Third Health and Medical Strategy Adds Infectious Diseases and Clinical Trial Acceleration
- NICE Methods Changes: What, When, Why, and the Expected Impact on Patient Access to Medicines
- Regulatory Efficiency in the Philippines: Good Submission Practice and Good Review Practices
- The European Health Data Space (EHDS): Breakthrough Moment in Sharing Health Data: Are We Ready for Implementation?
- Invisible in Evidence: Where Regulation Still Falls Short for Women
Japan’s Third Health and Medical Strategy Adds Infectious Diseases and Clinical Trial Acceleration
Japan’s Third Health and Medical Strategy Adds Infectious Diseases and Clinical Trial Acceleration
Japan's "Third Strategy" outlines the future direction of R&D, basic policies, and specific measures from fiscal year 2025 to fiscal year 2029.
×
